Clinical Trials Logo

Type 2 Diabetes Mellitus clinical trials

View clinical trials related to Type 2 Diabetes Mellitus.

Filter by:

NCT ID: NCT05331339 Completed - Clinical trials for Type 2 Diabetes Mellitus

Real-life Efficacy of Insulia® Tool in Patients Living With Type 2 Diabetes Treated With Basal Insulin Therapy as Part of a National Telemedicine Program (ETAPES)

INSULIA
Start date: November 2, 2022
Phase:
Study type: Observational

The purpose of this study was to evaluate the INSULIA digital tool (automation of basal insulin dose calculation in type 2 diabetes) within the framework of a French national telemedicine experimentation program (ETAPES) in a single-center study. The assumption is that a better metabolic control with this tool.

NCT ID: NCT05295160 Completed - Obesity Clinical Trials

Fasting-Associated Immune-metabolic Remission of Diabetes

FAIR
Start date: September 25, 2020
Phase: N/A
Study type: Interventional

People with a body mass index above 28 kg/m² and an onset of type 2 diabetes within the last 4 years had a remission (HbA1c <6.5% without medication) of diabetes in over 80% upon weight loss of 15 kg. Longer duration of diabetes reduced the chance of remission. The investigators will test whether there is a difference in remission upon weight loss of 15 kg using formula low calorie diets between subjects with a diabetes duration of <4 years vs. >8 years and oral treatment as primary end points. The immune metabolic programming of circulating monocytes will be investigated in detail regarding trained innate immunity and the endocrine responses will be determined using meal challenge tests.

NCT ID: NCT05261776 Completed - Clinical trials for Type 2 Diabetes Mellitus

The Effects of Pilates on Functional Capacity and Blood Glucose Levels in Adults With Diabetes Type 2

Start date: March 15, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effects of the Pilates training on Functional Capacity among adults with type 2 diabetes The aim of this study is to investigate the effects of the Pilates training on blood glucose response among adults with type 2 diabetes

NCT ID: NCT05248841 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers

Start date: March 8, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1 study to demonstrate pharmacokinetic and pharmacodynamic similarity between HEC-Glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers.

NCT ID: NCT05180604 Completed - Clinical trials for Cardiovascular Diseases

The Application and Evaluation of eHealth Literacy (eHL) Concept

eHL
Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This study aims to explore the effectiveness of experience learning program of eHealth care to improve the chronic patients' eHL in engaging with the eHealth care system on the indicators on eHealth literacy, patient health engagement, e-Health usage status among Chronic disease patients included type 2 diabetes patients, Chronic kidney disease, and Cardiovascular Diseases.

NCT ID: NCT05160974 Completed - Clinical trials for Type 2 Diabetes Mellitus

QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

Start date: December 30, 2021
Phase:
Study type: Observational

This is a local, prospective, non-interventional, regulatory post-marketing surveillance study. Adult patients with type 2 diabetes mellitus who are initiating Qtern as indicated by the MFDS will be included. 600 patients are followed up 12 weeks and at least 60 patients of the 600 patients are followed up 24 weeks. Patients will be treated as part of routine practice at Korean healthcare centers by accredited physicians. In this study, patients will receive Qtern as indicated in the locally approved prescribing information.

NCT ID: NCT05158244 Completed - Clinical trials for Type 2 Diabetes Mellitus

Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Start date: December 22, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and participant-blinded), sponsor-open study of PF-07081532. Study participants will receive the investigational product or placebo every day for 42 days. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple oral doses of PF-07081532 in participants with inadequately controlled type 2 diabetes mellitus, on metformin and optionally in non-diabetic participants with obesity.

NCT ID: NCT05146869 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Start date: December 30, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose and multiple-dose of DBPR108 tablets in Type 2 Diabetes Mellitus Patients.

NCT ID: NCT05114590 Completed - Clinical trials for Type 2 Diabetes Mellitus

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

Soli-CGM
Start date: January 27, 2022
Phase: Phase 4
Study type: Interventional

The purpose of the study was to demonstrate if iGlarLixi (Soliqua 100/33) would improve glycemic control (as measured by Time in Range) and glycemic variability in participants with very uncontrolled (HbA1c ≥ 9%) type 2 Diabetes Mellitus (T2DM) while on at least 2 oral antidiabetic drugs [OADs] with or without a glucagon-like peptide 1 receptor agonist [GLP1 RA]), as measured by continuous glucose monitoring (CGM). The total study duration per participant was approximately 22 weeks. Three site visits, 3 site or home visits, and up to 13 phone contacts were scheduled. - A screening period of up to 2 weeks - A run-in period of up to 2 weeks, including the baseline period - A 16-week, open-label treatment period - A 2-week post-treatment safety follow-up period

NCT ID: NCT05031871 Completed - Clinical trials for Type 2 Diabetes Mellitus

Pharmacokinetics of HR17031 Injection in Healthy Subjects

Start date: September 2, 2021
Phase: Phase 1
Study type: Interventional

To compare the pharmacokinetics and safety of HR17031 injection, SHR20004 injection and/or INS068 injection in healthy subjects